Clinical experience: practical management of five patients with cutaneous T-cell lymphoma (CTCL)-related symptoms.
There are now a wide variety of therapeutic options for managing patients with cutaneous T-cell lymphoma-related symptoms. These include skin-directed therapies such as psoralen with UVA irradiation (PUVA), topical chemotherapies such as mechlorethamine (nitrogen mustard) and carmustine (BCNU), electron beam radiation, and systemic therapies such as chemotherapy, photopheresis, and interferons. Although treatment algorithms exist for patients with early stage disease, often treatments are individualized, based on patient specific factors, cost, and accessibility of referral centers for specialized therapies. This article provides details of five real-life case studies to illustrate how cutaneous T-cell lymphoma management can be tailored to the needs of each individual patient.
Dummer
Reinhard
R
Department of Dermatology, University Hospital of Zurich, Switzerland. reinhard.dummer@usz.ch
Foss
Francine
F
Dreno
Brigitte
B
Bagot
Martine
M
D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002330:Carmustine / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003873:Dermatitis, Exfoliative / Q000188:drug therapy*; D004893:Erythema Nodosum / Q000188:drug therapy*; D005260:Female; D005363:Ficusin / Q000008:administration & dosage; D006801:Humans; D016410:Lymphoma, T-Cell, Cutaneous / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009182:Mycosis Fungoides / Q000188:drug therapy*; D011701:PUVA Therapy; D010789:Phototherapy; D012751:Sezary Syndrome / Q000188:drug therapy*; D012878:Skin Neoplasms / Q000188:drug therapy*
D000970:Antineoplastic Agents; D005363:Ficusin; D002330:Carmustine